Latest Strategic Planning News

Perenti’s underground mining arm, Barminco, has locked in a $500 million contract extension at the Agnew Gold Mine, reinforcing a decade-long partnership with Gold Fields and promising steady earnings.

Gentrack Group Limited reported a solid 9.8% revenue increase and a 34.7% jump in net profit for the first half of 2025, yet opted against paying an interim dividend.

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

Ballymore Resources has reported exceptional high-grade gold intersections from its ongoing Stage 5 underground drilling at the Dittmer Project, reinforcing the potential of a large gold system in North Queensland.

Universal Biosensors reports solid growth in its wine testing segment and outlines plans for a capital raise alongside the upcoming AQUASCOUT water testing device launch.

Elixir Energy has unveiled a strategic, fully funded plan to develop its extensive gas resources in Queensland’s Taroom Trough, aiming for initial production by late 2027. The company leverages its dominant acreage position alongside Shell’s operations and a fast-follower approach to unlock multi-TCF reserves.

SelfWealth Ltd has officially been acquired by Syfe’s holding company, with shareholders receiving $0.28 per share and the company set to delist from the ASX on May 8.

Mighty Kingdom Limited has completed its entitlement offer, raising approximately A$475,000 through the issuance of 95 million new shares, yet a significant shortfall remains to be placed with investors.

Quickstep Holdings Limited has completed its acquisition by ASDAM Operations Pty Ltd through a scheme of arrangement, resulting in a full board resignation and immediate delisting from the ASX. Shareholders received $0.575 per share as part of the transaction.

MedAdvisor Limited’s trading suspension has been lifted immediately following the release of an announcement about the outcome of a court application under the Corporations Act 2001.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Australian Strategic Materials (ASM) outlines progress on its Korean Metals Plant ramp-up, strategic plans for a US metals facility, and conditional funding support for the Dubbo Project, reinforcing its mine-to-metals supply chain ambitions.